Patents Assigned to BIOMED VALLEY DISCOVERIES, INC.
-
Patent number: 10716782Abstract: The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.Type: GrantFiled: November 22, 2019Date of Patent: July 21, 2020Assignee: BIOMED VALLEY DISCOVERIES, INC.Inventors: Saurabh Saha, Linping Zhang, Xiaoyan Michelle Zhang
-
Patent number: 10668055Abstract: The present invention provides, inter alia, methods of treating or ameliorating the effects of a cancer in a subject. The methods include administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 RAF inhibitor (such as dabrafenib) or another RAF inhibitor (such as regorafenib) or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Also provided are pharmaceutical compositions and kits for treating or ameliorating the effects of a cancer in a subject.Type: GrantFiled: December 19, 2014Date of Patent: June 2, 2020Assignee: BIOMED VALLEY DISCOVERIES, INC.Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
-
Patent number: 10617723Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×103-1×107 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided.Type: GrantFiled: March 28, 2014Date of Patent: April 14, 2020Assignees: BIOMED VALLEY DISCOVERIES, INC., THE JOHNS HOPKINS UNIVERSITYInventors: Saurabh Saha, Shibin Zhou, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 10604583Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: September 8, 2017Date of Patent: March 31, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha
-
Patent number: 10604582Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.Type: GrantFiled: September 16, 2015Date of Patent: March 31, 2020Assignees: The United States Of America, as represented by The Secretary, Department of Health, Biomed Valley Discoveries, Inc.Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
-
Patent number: 10485796Abstract: The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.Type: GrantFiled: November 10, 2017Date of Patent: November 26, 2019Assignee: BIOMED VALLEY DISCOVERIES, INC.Inventors: Saurabh Saha, Linping Zhang, Xiaoyan Michelle Zhang
-
Patent number: 10434174Abstract: Methods, pharmaceutical compositions, and kits for treating a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a platinum agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof.Type: GrantFiled: June 9, 2015Date of Patent: October 8, 2019Assignees: The United States of America, As Represented by the Secretary, Department of Health and Human Services, BioMed Valley Discoveries, Inc.Inventors: Saurabh Saha, Xiaoyan M. Zhang, Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire
-
Patent number: 10196443Abstract: Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: GrantFiled: August 17, 2017Date of Patent: February 5, 2019Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.Inventors: Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire, Saurabh Saha, Xiaoyan Michelle Zhang, Gary Decrescenzo, Dean Welsch
-
Patent number: 10183927Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.Type: GrantFiled: May 17, 2017Date of Patent: January 22, 2019Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals IncorporatedInventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
-
Patent number: 9951041Abstract: The present invention provides a malonate salt of a compound of formula (I): which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.Type: GrantFiled: May 17, 2017Date of Patent: April 24, 2018Assignee: BIOMED VALLEY DISCOVERIES, INC.Inventors: Gary DeCrescenzo, Dean Welsch, Jon G. Selbo, Ekaterina V. Albert, Emily M. Rigsbee
-
Patent number: 9861621Abstract: The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.Type: GrantFiled: June 28, 2016Date of Patent: January 9, 2018Assignee: Biomed Valley Discoveries, Inc.Inventors: Saurabh Saha, Linping Zhang, Xiaoyan Michelle Zhang
-
Patent number: 9790282Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: March 24, 2014Date of Patent: October 17, 2017Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.Inventors: Rimas J Orentas, Zhongyu Zhu, Crystal L Mackall, Dimiter S Dimitrov, Bradley St. Croix, Saurabh Saha
-
Patent number: 9765142Abstract: Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: GrantFiled: October 13, 2014Date of Patent: September 19, 2017Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.Inventors: Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire, Saurabh Saha, Xiaoyan Michelle Zhang, Gary Decrescenzo, Dean Welsch
-
Patent number: 9757424Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a glioma. Methods of this invention include administering to a subject in need thereof an effective amount of a first active agent, such as e.g., an angiotensin receptor blocker, an antifungal agent, a bisphosphonate, an oxytocin inhibitor, an interleukin-1 (IL-1) inhibitor, a cyclooxygenase inhibitor, an ?2? voltage-dependent calcium channel (VDCC) inhibitor, a dihydroorotate dehydrogenase inhibitor, a calcium channel blocker, a renal sodium-chloride symporter inhibitor, an a2 adrenergic agonist, a phenothiazine antipsychotic, a calcineurin inhibitor, a 5-HT agonist, an angiotensin-converting enzyme (ACE) inhibitor, a direct rennin inhibitor, or combinations thereof, and a second active agent, which is a chemotherapeutic agent. Compositions for treating or ameliorating the effects of a glioma are also provided.Type: GrantFiled: September 25, 2012Date of Patent: September 12, 2017Assignee: Biomed Valley Discoveries, Inc.Inventors: Reza Halse, Saurabh Saha, Jeffrey James Roix
-
Patent number: 9676746Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.Type: GrantFiled: January 29, 2016Date of Patent: June 13, 2017Assignees: BioMed Valley Discoveries, Inc., Vertex Pharmaceuticals IncorporatedInventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
-
Patent number: 9670177Abstract: The present invention provides a malonate salt of a compound of formula (I): which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.Type: GrantFiled: January 29, 2016Date of Patent: June 6, 2017Assignees: BioMed Valley Discoveries, Inc., Albany Molecular Research, Inc.Inventors: Gary DeCrescenzo, Dean Welsch, Jon G. Selbo, Ekaterina V. Albert, Emily M. Rigsbee
-
Publication number: 20170095575Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a molecularly targeted agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.Type: ApplicationFiled: June 9, 2015Publication date: April 6, 2017Applicants: BIOMED VALLEY DISCOVERIES, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OFInventors: Saurabh Saha, Xiaoyan M. Zhang, Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire
-
Publication number: 20160264662Abstract: Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: ApplicationFiled: October 13, 2014Publication date: September 15, 2016Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV, BIOMED VALLEY DISCOVERIES, INC.Inventors: Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire, Saurabh Saha, Xiaoyan Michelle Zhang, Gary Decrescenzo, Dean Welsch
-
Publication number: 20160045556Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.Type: ApplicationFiled: March 28, 2014Publication date: February 18, 2016Applicant: BIOMED VALLEY DISCOVERIES, INC.Inventors: Saurabh SAHA, Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER
-
Publication number: 20150018360Abstract: The present invention provides, inter alia, compositions containing enantiomerically pure (R)(+)-amisulpride or enantiomerically pure (R)(+)-sulpiride, optionally with dopamine receptor modulators. The present invention also provides compositions containing racemic (RS)-amisulpride or (RS)-sulpiride in combination with dopamine receptor modulators. Methods for preventing, treating, or ameliorating the effects of a metabolic disorder or key element thereof, for modulating blood glucose levels, and for preventing, treating, or ameliorating the effects of diabetes in a subject are also provided. Additionally, the present invention provides methods for counter-acting the dopamine antagonist activity of (S)-amisulpride in racemic (RS)-amisulpride, or the dopamine antagonist activity of (S)-sulpiride in racemic (RS)-sulpiride, administered to a subject to prevent, treat, or ameliorate the effects of a metabolic disorder.Type: ApplicationFiled: September 13, 2012Publication date: January 15, 2015Applicant: BIOMED VALLEY DISCOVERIES, INC.Inventors: Reza Halse, Jeffrey James Roix, Saurabh Saha